Search

Your search keyword '"Spigelman M"' showing total 7 results
Start Over Author "Spigelman M" Publisher international union against tuberculosis and lung disease
7 results on '"Spigelman M"'

2. Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts

Author

Oelofse, S., primary, Esmail, A., additional, Diacon, A. H., additional, Conradie, F., additional, Olayanju, O., additional, Ngubane, N., additional, Howell, P., additional, Everitt, D., additional, Crook, A. M., additional, Mendel, C. M., additional, Wills, G. H., additional, Olugbosi, M., additional, del Parigi, A., additional, Sun, E., additional, Calatroni, A., additional, Spigelman, M., additional, and Dheda, K., additional

Published
2021
Full Text
View/download PDF

3. A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB

Author

Tweed, C. D., primary, Wills, G. H., additional, Crook, A. M., additional, Amukoye, E., additional, Balanag, V., additional, Ban, A. Y.L., additional, Bateson, A. L.C., additional, Betteridge, M. C., additional, Brumskine, W., additional, Caoili, J., additional, Chaisson, R. E., additional, Cevik, M., additional, Conradie, F., additional, Dawson, R., additional, del Parigi, A., additional, Diacon, A., additional, Everitt, D. E., additional, Fabiane, S.M., additional, Hunt, R., additional, Ismail, A. I., additional, Lalloo, U., additional, Lombard, L., additional, Louw, C., additional, Malahleha, M., additional, McHugh, T. D., additional, Mendel, C. M., additional, Mhimbira, F., additional, Moodliar, R. N., additional, Nduba, V., additional, Nunn, A. J., additional, Sabi, I., additional, Sebe, M. A., additional, Selepe, R. A. P., additional, Staples, S., additional, Swindells, S., additional, van Niekerk, C. H., additional, Variava, E., additional, Spigelman, M., additional, and Gillespie, S. H., additional

Published
2021
Full Text
View/download PDF

5. Standards for clinical trials for treating TB.

Author

du Cros P, Greig J, Alffenaar JC, Cross GB, Cousins C, Berry C, Khan U, Phillips PPJ, Velásquez GE, Furin J, Spigelman M, Denholm JT, Thi SS, Tiberi S, Huang GKL, Marks GB, Turkova A, Guglielmetti L, Chew KL, Nguyen HT, Ong CWM, Brigden G, Singh KP, Motta I, Lange C, Seddon JA, Nyang'wa BT, Maug AKJ, Gler MT, Dooley KE, Quelapio M, Tsogt B, Menzies D, Cox V, Upton CM, Skrahina A, McKenna L, Horsburgh CR, Dheda K, and Marais BJ

Subjects
Humans, Biological Specimen Banks, Clinical Trials as Topic, Tuberculosis drug therapy
Abstract

BACKGROUND: The value, speed of completion and robustness of the evidence generated by TB treatment trials could be improved by implementing standards for best practice. METHODS: A global panel of experts participated in a Delphi process, using a 7-point Likert scale to score and revise draft standards until consensus was reached. RESULTS: Eleven standards were defined: Standard 1, high quality data on TB regimens are essential to inform clinical and programmatic management; Standard 2, the research questions addressed by TB trials should be relevant to affected communities, who should be included in all trial stages; Standard 3, trials should make every effort to be as inclusive as possible; Standard 4, the most efficient trial designs should be considered to improve the evidence base as quickly and cost effectively as possible, without compromising quality; Standard 5, trial governance should be in line with accepted good clinical practice; Standard 6, trials should investigate and report strategies that promote optimal engagement in care; Standard 7, where possible, TB trials should include pharmacokinetic and pharmacodynamic components; Standard 8, outcomes should include frequency of disease recurrence and post-treatment sequelae; Standard 9, TB trials should aim to harmonise key outcomes and data structures across studies; Standard 10, TB trials should include biobanking; Standard 11, treatment trials should invest in capacity strengthening of local trial and TB programme staff. CONCLUSION: These standards should improve the efficiency and effectiveness of evidence generation, as well as the translation of research into policy and practice.

Published
2023
Full Text
View/download PDF

7. Advancing the science in clinical trials for new TB drugs.

Author

Burman W, McNeeley D, Moulton LH, Spigelman M, and Vernon A

Subjects
Animals, Antitubercular Agents therapeutic use, Disease Models, Animal, Humans, Sputum microbiology, Clinical Trials, Phase II as Topic, Tuberculosis, Pulmonary drug therapy
Published
2008

Catalog

Books, media, physical & digital resources
See catalog results